Cart is empty The U.S. Food and Drug Administration has approved Onapgo (apomorphine hydrochloride) injection as the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in patients with advanced Parkinson disease, according to a news release from Supernus Pharmaceuticals.
Leave A Comment